EXPLORE!

Leading pharma companies announce branded versions of molnupiravir in India

  112 Views

#Pulmonary Medicine 

eMediNexus    21 January 2022

The DCGI based on the review of clinical data of Molnupiravir, has given restricted emergency use authorization for the drug to treat Covid-19 in adults with SpO2 > 93% and who have high risk of disease progression. 

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.